vs
Side-by-side financial comparison of Hologic (HOLX) and Primoris Services Corp (PRIM). Click either name above to swap in a different company.
Primoris Services Corp is the larger business by last-quarter revenue ($1.9B vs $1.0B, roughly 1.8× Hologic). Hologic runs the higher net margin — 17.1% vs 2.8%, a 14.3% gap on every dollar of revenue. On growth, Primoris Services Corp posted the faster year-over-year revenue change (6.7% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $121.1M). Over the past eight quarters, Primoris Services Corp's revenue compounded faster (14.7% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Primoris Services Corporation is a publicly traded specialty construction and infrastructure company based in the United States, with a particular focus on pipelines for natural gas, wastewater and water. As of 2014 it was a Fortune 1000 company.
HOLX vs PRIM — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.9B |
| Net Profit | $179.1M | $51.7M |
| Gross Margin | 56.0% | 9.4% |
| Operating Margin | 22.6% | 4.2% |
| Net Margin | 17.1% | 2.8% |
| Revenue YoY | 2.5% | 6.7% |
| Net Profit YoY | -10.9% | -4.2% |
| EPS (diluted) | $0.79 | $0.94 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $1.9B | ||
| Q3 25 | $1.0B | $2.2B | ||
| Q2 25 | $1.0B | $1.9B | ||
| Q1 25 | $1.0B | $1.6B | ||
| Q4 24 | $1.0B | $1.7B | ||
| Q3 24 | $988.0M | $1.6B | ||
| Q2 24 | $1.0B | $1.6B | ||
| Q1 24 | $1.0B | $1.4B |
| Q4 25 | $179.1M | $51.7M | ||
| Q3 25 | $187.2M | $94.6M | ||
| Q2 25 | $194.9M | $84.3M | ||
| Q1 25 | $-17.4M | $44.2M | ||
| Q4 24 | $201.0M | $54.0M | ||
| Q3 24 | $178.6M | $58.4M | ||
| Q2 24 | $194.5M | $49.5M | ||
| Q1 24 | $169.9M | $18.9M |
| Q4 25 | 56.0% | 9.4% | ||
| Q3 25 | 55.6% | 10.8% | ||
| Q2 25 | 56.3% | 12.3% | ||
| Q1 25 | 37.5% | 10.4% | ||
| Q4 24 | 56.8% | 10.6% | ||
| Q3 24 | 56.4% | 12.0% | ||
| Q2 24 | 55.4% | 11.9% | ||
| Q1 24 | 53.3% | 9.4% |
| Q4 25 | 22.6% | 4.2% | ||
| Q3 25 | 22.6% | 6.3% | ||
| Q2 25 | 24.9% | 6.7% | ||
| Q1 25 | -0.7% | 4.3% | ||
| Q4 24 | 22.5% | 5.0% | ||
| Q3 24 | 23.3% | 6.0% | ||
| Q2 24 | 24.1% | 5.5% | ||
| Q1 24 | 20.7% | 3.1% |
| Q4 25 | 17.1% | 2.8% | ||
| Q3 25 | 17.8% | 4.3% | ||
| Q2 25 | 19.0% | 4.5% | ||
| Q1 25 | -1.7% | 2.7% | ||
| Q4 24 | 19.7% | 3.1% | ||
| Q3 24 | 18.1% | 3.5% | ||
| Q2 24 | 19.2% | 3.2% | ||
| Q1 24 | 16.7% | 1.3% |
| Q4 25 | $0.79 | $0.94 | ||
| Q3 25 | $0.84 | $1.73 | ||
| Q2 25 | $0.86 | $1.54 | ||
| Q1 25 | $-0.08 | $0.81 | ||
| Q4 24 | $0.87 | $0.98 | ||
| Q3 24 | $0.75 | $1.07 | ||
| Q2 24 | $0.82 | $0.91 | ||
| Q1 24 | $0.72 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $535.5M |
| Total DebtLower is stronger | $2.5B | $469.9M |
| Stockholders' EquityBook value | $5.2B | $1.7B |
| Total Assets | $9.2B | $4.4B |
| Debt / EquityLower = less leverage | 0.48× | 0.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $535.5M | ||
| Q3 25 | $2.2B | $431.4M | ||
| Q2 25 | $1.9B | $390.3M | ||
| Q1 25 | $1.6B | $351.6M | ||
| Q4 24 | $2.0B | $455.8M | ||
| Q3 24 | $2.3B | $352.7M | ||
| Q2 24 | $2.4B | $207.4M | ||
| Q1 24 | $2.2B | $177.6M |
| Q4 25 | $2.5B | $469.9M | ||
| Q3 25 | $2.5B | $486.0M | ||
| Q2 25 | $2.5B | $603.1M | ||
| Q1 25 | $2.5B | $612.0M | ||
| Q4 24 | $2.5B | $734.8M | ||
| Q3 24 | $2.5B | $903.7M | ||
| Q2 24 | $2.5B | $933.0M | ||
| Q1 24 | $2.6B | $951.7M |
| Q4 25 | $5.2B | $1.7B | ||
| Q3 25 | $5.0B | $1.6B | ||
| Q2 25 | $4.8B | $1.5B | ||
| Q1 25 | $4.6B | $1.4B | ||
| Q4 24 | $4.8B | $1.4B | ||
| Q3 24 | $5.1B | $1.4B | ||
| Q2 24 | $5.0B | $1.3B | ||
| Q1 24 | $4.8B | $1.2B |
| Q4 25 | $9.2B | $4.4B | ||
| Q3 25 | $9.0B | $4.6B | ||
| Q2 25 | $8.8B | $4.5B | ||
| Q1 25 | $8.5B | $4.2B | ||
| Q4 24 | $8.7B | $4.2B | ||
| Q3 24 | $9.2B | $4.2B | ||
| Q2 24 | $8.9B | $4.0B | ||
| Q1 24 | $8.7B | $4.0B |
| Q4 25 | 0.48× | 0.28× | ||
| Q3 25 | 0.50× | 0.30× | ||
| Q2 25 | 0.52× | 0.39× | ||
| Q1 25 | 0.55× | 0.42× | ||
| Q4 24 | 0.53× | 0.52× | ||
| Q3 24 | 0.49× | 0.67× | ||
| Q2 24 | 0.51× | 0.72× | ||
| Q1 24 | 0.53× | 0.76× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $142.9M |
| Free Cash FlowOCF − Capex | $215.2M | $121.1M |
| FCF MarginFCF / Revenue | 20.5% | 6.5% |
| Capex IntensityCapex / Revenue | 1.4% | 1.2% |
| Cash ConversionOCF / Net Profit | 1.28× | 2.76× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $340.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $142.9M | ||
| Q3 25 | $355.1M | $182.9M | ||
| Q2 25 | $343.3M | $78.5M | ||
| Q1 25 | $169.4M | $66.2M | ||
| Q4 24 | $189.3M | $298.3M | ||
| Q3 24 | $367.0M | $222.5M | ||
| Q2 24 | $405.8M | $16.1M | ||
| Q1 24 | $292.4M | $-28.5M |
| Q4 25 | $215.2M | $121.1M | ||
| Q3 25 | $341.4M | $148.4M | ||
| Q2 25 | $330.5M | $45.3M | ||
| Q1 25 | $153.9M | $25.6M | ||
| Q4 24 | $172.5M | $270.0M | ||
| Q3 24 | $350.6M | $158.8M | ||
| Q2 24 | $385.3M | $-8.1M | ||
| Q1 24 | $279.6M | $-38.9M |
| Q4 25 | 20.5% | 6.5% | ||
| Q3 25 | 32.5% | 6.8% | ||
| Q2 25 | 32.3% | 2.4% | ||
| Q1 25 | 15.3% | 1.6% | ||
| Q4 24 | 16.9% | 15.5% | ||
| Q3 24 | 35.5% | 9.6% | ||
| Q2 24 | 38.1% | -0.5% | ||
| Q1 24 | 27.5% | -2.8% |
| Q4 25 | 1.4% | 1.2% | ||
| Q3 25 | 1.3% | 1.6% | ||
| Q2 25 | 1.3% | 1.8% | ||
| Q1 25 | 1.5% | 2.5% | ||
| Q4 24 | 1.6% | 1.6% | ||
| Q3 24 | 1.7% | 3.9% | ||
| Q2 24 | 2.0% | 1.5% | ||
| Q1 24 | 1.3% | 0.7% |
| Q4 25 | 1.28× | 2.76× | ||
| Q3 25 | 1.90× | 1.93× | ||
| Q2 25 | 1.76× | 0.93× | ||
| Q1 25 | — | 1.50× | ||
| Q4 24 | 0.94× | 5.53× | ||
| Q3 24 | 2.05× | 3.81× | ||
| Q2 24 | 2.09× | 0.32× | ||
| Q1 24 | 1.72× | -1.50× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
PRIM
| Energy Segment | $1.2B | 64% |
| Unit Price Contracts | $473.7M | 25% |
| Cost Reimbursable Contracts | $121.3M | 7% |
| Other | $74.9M | 4% |
